MIST vs. CCCC
MIST (Milestone Pharmaceuticals Inc.) and CCCC (C4 Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, MIST returned -26.09%/yr vs -35.79%/yr for CCCC. At a 0.21 correlation, their price movements are largely independent.
Performance
MIST vs. CCCC - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MIST achieves a -35.15% return, which is significantly lower than CCCC's 115.71% return.
MIST
- 1D
- 0.77%
- 1M
- -7.09%
- YTD
- -35.15%
- 6M
- -36.71%
- 1Y
- -22.49%
- 3Y*
- -25.36%
- 5Y*
- -26.09%
- 10Y*
- —
CCCC
- 1D
- -0.72%
- 1M
- 15.73%
- YTD
- 115.71%
- 6M
- 97.13%
- 1Y
- 190.14%
- 3Y*
- 12.55%
- 5Y*
- -35.79%
- 10Y*
- —
MIST vs. CCCC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
MIST Milestone Pharmaceuticals Inc. | -35.15% | -14.41% | 41.32% | -57.83% | -39.54% | -2.24% | -5.63% |
CCCC C4 Therapeutics, Inc. | 115.71% | -46.94% | -36.28% | -4.24% | -81.68% | -2.81% | 24.55% |
Correlation
The correlation between MIST and CCCC is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Oct 2, 2020 | 0.21 |
Fundamentals
MIST:
$170.67M
CCCC:
$519.43M
MIST:
-$0.49
CCCC:
-$1.18
MIST:
63.69
CCCC:
12.65
MIST:
4.73
CCCC:
2.22
MIST:
$1.78M
CCCC:
$28.71M
MIST:
$1.75M
CCCC:
$26.90M
MIST:
-$63.04M
CCCC:
-$107.31M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MIST vs. CCCC — Risk / Return Rank
MIST
CCCC
MIST vs. CCCC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Milestone Pharmaceuticals Inc. (MIST) and C4 Therapeutics, Inc. (CCCC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MIST | CCCC | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.17 | ||
| Sortino ratioReturn per unit of downside risk | -2.70 | ||
| Omega ratioGain probability vs. loss probability | 1.03 | 1.32 | -0.30 |
| Calmar ratioReturn relative to maximum drawdown | -0.34 | 3.67 | -4.02 |
| Martin ratioReturn relative to average drawdown | -0.63 | 7.13 | -7.76 |
Loading charts...
Drawdowns
MIST vs. CCCC - Drawdown Comparison
The maximum MIST drawdown since its inception was -97.60%, roughly equal to the maximum CCCC drawdown of -97.82%. Use the drawdown chart below to compare losses from any high point for MIST and CCCC.
Loading charts...
Drawdown Indicators
| MIST | CCCC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.60% | -97.82% | +0.22% |
Max Drawdown (1Y)Largest decline over 1 year | -65.76% | -52.10% | -13.66% |
Max Drawdown (3Y)Largest decline over 3 years | -82.31% | -90.00% | +7.69% |
Max Drawdown (5Y)Largest decline over 5 years | -93.13% | -97.82% | +4.69% |
Current DrawdownCurrent decline from peak | -95.17% | -91.84% | -3.33% |
Average DrawdownAverage peak-to-trough decline | -78.34% | -72.01% | -6.33% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.63% | 26.79% | +8.84% |
Volatility
MIST vs. CCCC - Volatility Comparison
The current volatility for Milestone Pharmaceuticals Inc. (MIST) is 12.76%, while C4 Therapeutics, Inc. (CCCC) has a volatility of 27.58%. This indicates that MIST experiences smaller price fluctuations and is considered to be less risky than CCCC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MIST | CCCC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.76% | 27.58% | -14.82% |
Volatility (6M)Calculated over the trailing 6-month period | 54.45% | 63.03% | -8.58% |
Volatility (1Y)Calculated over the trailing 1-year period | 83.41% | 101.00% | -17.59% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 77.73% | 117.55% | -39.82% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 105.01% | 112.85% | -7.84% |
Dividends
MIST vs. CCCC - Dividend Comparison
Neither MIST nor CCCC has paid dividends to shareholders.
Financials
MIST vs. CCCC - Financials Comparison
This section allows you to compare key financial metrics between Milestone Pharmaceuticals Inc. and C4 Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MIST and CCCC have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CCCC has higher volatility (27.58%) compared to MIST (12.76%). In terms of maximum drawdown, MIST dropped -97.60% vs CCCC's -97.82%.
CCCC currently has the higher Sharpe Ratio (1.90 vs -0.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MIST and CCCC
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer